New abilities in treatment of bronchoobstructive syndrome in children
Abstract
The authors performed an opened randomized study of therapeutic efficacy of various medications for bronchoobstructive syndrome (BOS) treatment in different aged children. Sixty nine children aged from 1.5 months to 8 years were observed; they were divided into 2 groups equal in age, demographic and functional parameters according to medications received. Each of the groups was divided into subgroups according to BOS severity. The medications efficacy was scored for the patients’ general status, dyspnoea, cough, wheezing, the lung auscultation and for visual and mathematical characteristics of bronchophonogram which are objective parameters.
The data obtained evidence that the inhaled nebulized therapy with the modern bronchodilating drugs, such as Berotec, Salgim, ipratropium bromide, Berodual is effective in most cases (more than 97%): clinical symptoms were solved, the patients’ general status and lung function parameters became normal confirmed by normal values of bronchophonography. The nebulized therapy with ipratropium bromide (Atrovent) was reliably shown to be optimal for BOS treatment in infants in term of tolerability, efficiency and safety.
About the Authors
A. B. Malakhov
Ивановская государственная медицинская академия; детская клиническая больница скорой помощи
Russian Federation
Russian Federation
S. A. Makarova
Ивановская государственная медицинская академия; детская клиническая больница скорой помощи
Russian Federation
Russian Federation
M. A. Malakhov
Ивановская государственная медицинская академия; детская клиническая больница скорой помощи
Russian Federation
Russian Federation
V. S. Malyshev
Ивановская государственная медицинская академия; детская клиническая больница скорой помощи
Russian Federation
Russian Federation
N. A. Sellverstova
Ивановская государственная медицинская академия; детская клиническая больница скорой помощи
Russian Federation
Russian Federation
References
1. Геппе Н А . Небулайзерная терапия при бронхиальной астме у детей. Пульмонология 1999; 2: 42—48.
2. Неотложная терапия бронхиальной астмы у детей: Пособие для врачей/Геппе Н.А., Коростовцев Д.С., Малахов А.Б и др.; Под ред. А.А.Баранова. М.; 1999.
3. Середа Е.В. Современная терапия при бронхитах у детей. Детский доктор 1999; 2: 30—32.
4. Beck R. Use of ipratropium bromide by inhalation in treatment of acute asthma in children. Arch. Pediatr. 1995; 2 (suppl.2): 145S—148S.
5. Bisgaard Ii. Patient-related factors in nebulized drug delivery to children. Eur. Respir. Rev. 1997; 51 (7): 376—377.
6. Jedrys U., Kurzawa R. et al. Evaluation of the bronchodilatory activity of berodual and it’s components: fenoterol and ipratropium bromide in children with bronchial asthma. Pneumonol. Allergol. Pol. 1994; 62 (11—12): 615—622.
7. Muers M.F. Overview of nebuliser treatment. Thorax 1997; 52 (suppl.2): s25—s30.
8. Quershi F., Pestian J. et al. Effect of nebulized ipratropium bromide on the hospitalization rates of children with asthma. N. Engl. J. Med. 1998; 339 (5): 1030—1035.
9. Rubin B.K., Albers G.M. Use of anticholinergic bronchodilation in children. Am. J. Med. 1996; 100 (la ): 49s—53s.
10. Schuh S., Johnson D.W., Callahan S. et al. Efficacy of frequent nebulizer ipratropium bromide added to frequent high-dose albuterol therapy in severe asthma. J. Pediatr. 1995; 126 (4): 639—645.
11. Watson W.A., Becker A.B., Simons F.E. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J. Allergy Clin. Immunol. 1988; 82 (6): 1012—1018.
Review
For citations:
Malakhov A.B., Makarova S.A., Malakhov M.A., Malyshev V.S., Sellverstova N.A. New abilities in treatment of bronchoobstructive syndrome in children. PULMONOLOGIYA. 2001;(4):55-59. (In Russ.)
Views:
239
Email this article 